Description
The innovative Sievers Eclipse BET platform decreases assay setup time by up to 85% and reduces Limulus Amebocyte Lysate (LAL) reagent use by up to 90% while meeting all requirements of the harmonized pharmacopeia: USP <85>, EP 2.6.14, and JP 4.01. Through groundbreaking technology, the Eclipse platform significantly decreases pipetting steps, reduces operator-to-operator variability, and simplifies assay setup. The Eclipse platform leverages precise microfluidic liquid handling and embedded endotoxin to automate kinetic chromogenic assays. The throughput of 21 samples per plate is maintained without the complexity of robotics or the time and technique demand of a traditional assay.